Gerald W. Verhaegh - Concepedia

Author

Gerald W. Verhaegh

Also Known As

Frank Smit, G Verhaegh, G W Verhaegh, G. Verhaegh, G. W Verhaegh, G. W. C. T. Verhaegh, G. W. Verhaegh, G.W. Verhaegh, G.W.C.T. Verhaegh, GERALD VERHAEGH

161

Publications

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center Radboud Institute for Molecular Life Sciences Erasmus University Rotterdam Leiden University

About

Gerald W. Verhaegh is an author at Radboud University Nijmegen specializing in medicine, urology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	3.5K
2	Cell Biology	10	11	1.9K
3	Public Health	2	2	181
4	Cellular Physiology	2	2	23
5	Natural Sciences	1	1	31

Gerald W. Verhaegh

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Marion J.G. Bussemakers, Adrie van Bokhoven, Gerald W. Verhaegh, PubMed Tumor BiologyUrologyOncologyDd3 GeneGenitourinary Cancer	1999	1.1K
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Jacques B de Kok, Gerald W. Verhaegh, Rian Roelofs, PubMed Prognostic BiomarkersUrologyPerineural InvasionGenitourinary CancerCancer Detection	2002	617
Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles Uta Erdbrügger, Charles J. Blijdorp, Irene V. Bijnsdorp, Journal of Extracellular Vesicles	2021	370
Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer Daphne Hessels, Frank Smit, Gerald W. Verhaegh, Clinical Cancer Research	2007	333
ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53 Stéphanie Courtois, Gerald W. Verhaegh, Sophie North, Oncogene Tumor BiologyWild-type P53MedicineGrowth SuppressionCell Proliferation	2002	259
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study Elizabeth Bancroft, Elizabeth Page, Elena Castro, European Urology	2014	247
TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming Kristiina Iljin, Maija Wolf, Henrik Edgren, Cancer Research	2006	236
MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma Kerstin Boll, Kristin Reiche, Katharina Kasack, Oncogene UrologyProstate CarcinomaMicrorna DetectionSmall RnaProstatic Disease	2012	214
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer Lambertus A. Kiemeney, Patrick Sulem, Søren Besenbacher, Nature Genetics Tumor BiologyUrinary Bladder CancerUrologyUrological ResearchGenitourinary Cancer	2010	193
Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma Karin Grabmaier, Mirjam CA de Weijert, Gerald W. Verhaegh, Oncogene UrologyGenitourinary CancerKidney ResearchStrict RegulationMedicine	2004	182

Page 1